Ubidecarenone - Berg Pharma

Drug Profile

Ubidecarenone - Berg Pharma

Alternative Names: API-31510; BP 31510; BPM 31510-IV; BPM-31510; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; Compound 31510; CoQ10 - Cytotech; Ubiquinone injectable nanosuspension

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Cytotech Labs
  • Developer Berg Pharma; National Cancer Institute (USA); Stanford University; University of Miami
  • Class Antineoplastics; Benzoquinones; Cardiotonics; Coenzymes; Small molecules
  • Mechanism of Action Antioxidants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Glioblastoma; Glioma
  • Phase I Epidermolysis bullosa; Solid tumours
  • No development reported Basal cell cancer; Lung cancer; Squamous cell cancer; Wounds
  • Discontinued Leukaemia

Most Recent Events

  • 12 Apr 2017 Chemical structure information added
  • 01 Apr 2017 Pharmacodynamics data from in-vitro studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 01 Mar 2017 Berg completes a phase I trial in Healthy volunteers in USA (NCT03002935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top